Bristol-Myers Squibb Co.

345 Park Avenue,
New York, New York 10154
United States,
(212) 546-4000

Bristol-Myers Squibb Company is a life science company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. The Company's pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes. The majority of Bristol-Myers Squibb's revenue comes from products in the following therapeutic classes: cardiovascular; virology, including human immunodeficiency virus (HIV) infection; oncology; neuroscience; immunoscience; and metabolics. Bristol-Myers Squibb Company was originally established in 1887 and is based in New York City.

M&A Summary

Buy vs Sell

Year ≤ '13 '14 '15 '16 '17 '18 T
Buy (1.6/yr) # 8 3 2 2 1 - 16
vol $19.5B $1.2B $1.6B $320M $22.6B
Sell (0.4/yr) # 6 1 - 1 - - 8
vol $9.4B $2.7B $350M $12.5B

Top M&A Advisors

Financial Deals
Sign-up to View
Sign-up to View
Sign-up to View
Legal Deals
Sign-up to View
Sign-up to View
Sign-up to View

Deal Values

> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest Dupont Pharmaceuticals Company
$7.8B (2001-10-02)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View
Largest Clairol, Inc.
$5.0B (2001-05-22)

According to our data here at Mergr, Bristol-Myers Squibb has acquired 17 companies, including 8 in the last 5 years. A total of 2 acquisitions came from private equity firms. It has also divested 8 assets.

Bristol-Myers Squibb’s largest acquisition to date was in 2001, when it acquired Dupont Pharmaceuticals Company for $7.8B. It’s largest disclosed sale occurred in 2001, when it sold Clairol to The Procter & Gamble for $5.0B. Bristol-Myers Squibb has acquired in 7 different US states, and 3 countries. The Company’s most targeted sectors include life science (100%).

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 411 life science companies that have made at least 1 acquisition, 15 have acquired at least 5 companies, and 2 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 29 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 5 platform acquisitions.

Join Mergr and gain access to Bristol-Myers Squibb’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.

What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
  • 3.4K Private Equity Firms
  • 120K M&A Transactions
  • 129K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.8K M&A Advisors
    (Investment Banks and Law Firms)
  • 35K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.